Axsome shares jump as settlement will keep Teva's Auvelity generic off the market until 2038
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press release. Entrance of the generic will be delayed by an additional six months, until March 31, 2039, if Axsome gains an FDA pediatric exclusivity extension for its treatment.
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...
Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.
EST Teva (TEVA) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback